EUCTR2009-017169-53-FR进行中（未招募）1 期
A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for the treatment of endometriosis in adolescents over a treatment period of 52 weeks - Visanne Study to assess safety in adolescents
Bayer HelathCare AG, Leverkusen, D-51368 Germany0 个研究点目标入组 111 人开始时间: 2010年12月14日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 111
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Female adolescents after menarche (12 – less than 18 years of age at screening)
- •2. Dysmenorrhea of at least moderate intensity, with or without chronic pelvic pain, for at least 2 cycles in the previous 4 months and one of the following conditions:
- •clinically suspected endometriosis based on the presence of pelvic pain incompletely relieved by non steroidal anti-inflammatory drugs
- •any abdominal pain associated with ultrasound findings suggestive of endometriosis (abdominal, vaginal or rectal; only after additional specific consent and assent);
- •failure of surgical treatment for endometriosis (with cyclic or chronic pelvic pain of at least 4 months duration after previous surgical confirmation of endometriosis)
- •3. Threshold for endometriosis-associated pelvic pain (EAPP) score: at least 30 on a 100 units visual analog scale retrospectively evaluated at screening for the last 4 weeks
- •4. Good general health (except for findings related to endometriosis, as evidenced by medical history, physical/ gynecological examination and laboratory tests)
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Absence of endometriosis at laparoscopy
- •2. Previous application of hormonal agents including oral contraceptives within 2 months, progestins, danazol within 3 months, and Gonadotropin Releasing Hormone (GnRH) agonists within 6 months prior to start of treatment
- •3. Chronic pelvic pain that might be related to genitourinary disease or to chronic or recurrent gastrointestinal disease, including irritable bowel syndrome (defined as a disease characterized by pain relieved by defecation and irregular defecation patterns lasting at least 3 months)
- •4. Clinically established need for primary surgical treatment of endometriosis
- •5. Pregnancy or breast feeding
- •6. Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study medication
- •7. Diseases that may influence bone mineral density eg. anorexia, inflammatory bowel diseases (Crohn´s disease, ulcerative colitis) and celiac disease
- •8. Any disease or condition that may worsen under hormonal treatment according to the assessment and opinion of the investigator.
- •9. Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results
- •10. Undiagnosed abnormal genital bleeding
- •11. Amenorrhea (previous 3 months before screening)
- •12. Hypersensitivity to any ingredient of the study drug
- •13. Abuse of alcohol, drugs, or medicine (e.g. laxatives)
- •14. Clinically relevant findings at general physical or gynecological examination
- •15. Major surgery scheduled for the study period
- •16. Laboratory values outside inclusion range before allocation of treatment.
- •17. Any medication that could result in excessive accumulation, impaired metabolism, or altered excretion of the study drug or might interfere with the conduct of the study or the interpretation of the results such as that described in Section 6.9
研究者
相似试验
进行中（未招募）
不适用
A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for the treatment of endometriosis in adolescents over a treatment period of 52 weeksMedDRA version: 14.1Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2009-017169-53-CZBayer HealthCare AG, Leverkusen, D-51368 Germany100
进行中（未招募）
不适用
A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for the treatment of endometriosis in adolescents over a treatment period of 52 weeksMedDRA version: 15.0Level: PTClassification code 10014778Term: EndometriosisSystem Organ Class: 10038604 - Reproductive system and breast disordersEndometriosisEUCTR2009-017169-53-FIBayer HealthCare AG, Leverkusen, D-51368 Germany100
进行中（未招募）
不适用
A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for thetreatment of endometriosis in adolescents over a treatment period of 52 weeksEUCTR2009-017169-53-DEBayer HealthCare AG100
进行中（未招募）
不适用
A multi-center, open label, single-arm study to investigate the safety and efficacy of daily oral administration of 2 mg dienogest tablets for the treatment of endometriosis in adolescents over a treatment period of 52 weeksEndometriosisEUCTR2009-017169-53-ATBayer HealthCare AG, Leverkusen, D-51368 Germany100
进行中（未招募）
1 期
An open-label, multi-center, single-arm study to evaluate the efficacy of nilotinib in adult patients with metastatic or unresectable gastrointestinal stromal tumors in first line treatmentEUCTR2008-000358-11-DEovartis Pharma GmbH40